No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - AIM-listed Genedrive said on Friday that shareholder David Nugent had shown "willingness" to make a cash injection into the point-of-care pharmacogenetic testing company.
The company said that since its general meeting on 15 October, it has "continued to engage constructively" with Nugent - who has a 16% interest in the group - about financing options.
Genedrive said Nugent "has recently indicated a willingness" to make a direct cash injection into the company by way of a loan of up to 1m on terms to be agreed between the parties.
"Whilst there can be no certainty that this additional funding will be received the company welcomes this indication of potential additional financial support from David Nugent and further announcements will be made in due course," it said.
At 1010 GMT, the shares were up 10% at 0.94p.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.